Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

Research output: Contribution to journalJournal articleResearchpeer-review

  • Vilsbøll, Tina
  • Birgitte Brock
  • Hans Perrild
  • K Levin
  • Hans-Henrik Lervang
  • Klaus Erik Kølendorf
  • T Krarup
  • Ole Schmitz
  • M Zdravkovic
  • Xuan Le Thi Thanh
  • Madsbad, Sten
To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test.
Original languageEnglish
JournalDiabetic Medicine
Volume25
Issue number2
Pages (from-to)152-6
Number of pages5
ISSN0742-3071
DOIs
Publication statusPublished - 1 Feb 2008

ID: 34070207